Precision Biosciences Publications. (2025) American Society of The Most Read ranking is based on the num
(2025) American Society of The Most Read ranking is based on the number of downloads in the last 60 days from papers published on the Journal of Precision Biosciences within the last 12 months. et al. For more information about our programs, see our current corporate deck. (Stock Exchange Nasdaq) on MarketScreener Precision BioSciences, Inc. Martin, Aaron, et. Browse our publications catalogue to learn about our research. Shah, B. This study showed Personalized peptide engineering offers precise, adaptive, and safe therapeutic solutions, optimizing health outcomes while minimizing adverse effects and systemic toxicity. Mischler, Adam, et. Traci REDDICK, Associate Director | Cited by 10 | of Precision Biosciences, Durham | Read 4 publications | Contact Traci REDDICK - Publication describes how the unique qualities of ARCUS nucleases contribute to precise and efficient gene editing for gene insertion, single base editing, specific small and large deletions, Precision BioSciences, Inc. announced the publication of a peer-reviewed manuscript titled ?High-Efficiency Homology-Directed Insertion into the Genome using the Engineered Homing Latest earnings report from the company Precision BioSciences, Inc. D. Journal for ImmunoTherapy of Cancer. (2025) American Association for the Study of Liver Diseases. al. announced publication in the journal Nature Metabolism of a peer reviewed manuscript titled ?Efficient elimination of MELAS-associated m. Unlike some editing technologies that have been designed as research tools and Our team includes pioneers in genome editing and leaders in cell and gene therapy who are committed to solving significant medical problems. Find 28 researchers and browse 1 departments, publications, full-texts, contact details and general information related to Precision Biosciences | Durham, United States | - Publication describes how the unique qualities of ARCUS nucleases contribute to precise and efficient gene editing for gene insertion, single base editing, specific small and large deletions, In vivo gene editing has the potential to permanently cure genetic diseases. (2025) American Society of Gene & Cell Therapy Jucov Yuen, MF. Discover High-efficiency homology-directed insertion into the genome using ARCUS nucleases. , a clinical stage gene editing company utilizing its novel proprietary ARCUS ® platform to develop in vivo gene editing therapies for high unmet need Precision BioSciences, Inc. Precision optimizes its CAR T therapy candidates for immune cell expansion in the body by maintaining a high proportion of naïve and central memory CAR T cells throughout the Precision BioSciences, Inc. American Society of Clinical Oncology (ASCO) 2021 The Journal of Precision Biosciences is a multidisciplinary, peer-reviewed journal dedicated to advancing research in the field of precision biosciences. - Publication describes how the unique qualities of ARCUS nucleases contribute to precise and efficient gene editing for gene insertion, single base editing, specific small and large deletions, Pires, M. (Nasdaq: DTIL), a clinical stage gene editing company utilizing its novel proprietary ARCUS® platform to develop in vivo gene edi PDF | On Jun 9, 2025, Tufael published PRECISION BIOSCIENCES | Find, read and cite all the research you need on ResearchGate Precision BioSciences, Inc. This study determines the role of lifestyle medicine, emphasizing the impact of nutrition, physical activity, stress management, sleep hygiene, and social connections on health outcomes. (Nasdaq: DTIL), an advanced gene editing company utilizing its novel proprietary ARCUS® platform to develop in Latest earnings report from the company Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage gene editing company developing ARCUS-based ex vivo allogeneic CAR T and in vivo gene editing th Precision BioSciences, Inc. The journal focuses on the integra. , et. (2025) American Society of Gene & Cell Therapy. Shoop, Wendy, et al. Society for Immunotherapy of Cancer (SITC) 2021 Annual Meeting. al. 3243G mutant . (2025) Nucleic Acids Research, Vol 53, Issue 18. Yuen, MF. today announced publication in the journal Nature Metabolism of a peer reviewed manuscript titled “Efficient elimination of MELAS-associated m. (Stock Exchange Deutsche Boerse AG) on MarketScreener Precision optimizes its CAR T therapy candidates for immune cell expansion in the body by maintaining a high proportion of naïve and central memory CAR T cells throughout the Precision Biosciences Announces Initial Safety And Antiviral Activity Of Pbgene-Hbv Published on 02/19/2025 at 07:04 am EST Reuters This article is reserved for members Precision Biosciences Innovation Hub Publications Browse our publications catalogue to learn about our research. 3243G mutant Precision BioSciences said Monday its investigational new drug application for PBGENE-HBV in vivo gene editing program has received the US Food and Drug Administration's clearance to treat chronic Precision BioSciences, Inc. 9,6 (2021).